Skip to main content

AbbVie (NYSE:ABBV) Is a Classic Buy the Dip Candidate

Monday, February 1, 2021 | Chris Markoch
AbbVie (NYSE:ABBV) Is a Classic Buy the Dip Candidate

AbbVie (NYSE:ABBV) will report earnings before the market opens on February 3, 2021. The biopharmaceutical giant is expected to post earnings per share and revenue that mark both a sequential and year-over-year gain. The company is also expected to issue forward guidance that suggests 2021 will continue this growth trend.

But you wouldn’t believe it by looking at the stock price. ABBV stock has been falling since reaching a nearly three-year high in mid-January. However the dip in the biopharma stock is easily explained.

AbbVie Recently Began Trading Ex-Dividend

First, the company’s ex-dividend date passed on January 14. An ex-dividend date is the first date that a company’ s stock trades without the dividend. Any shareholder that is on record by the ex-dividend date receives the upcoming dividend. Those that aren’t will not. That’s why the period immediately preceding the ex-dividend date can be a time when a company’s stock goes up.

However, it’s 2021 and there are many active day traders that likely availed themselves of a dividend capture strategy. This allows them to buy the stock before the ex-dividend date and sell it immediately afterwards. They still collect the dividend, but don’t maintain a long position in the stock.

But dividend capture doesn’t explain the nearly 10% drop in ABBV stock. For that we have to blame recent events.

Quality Stocks Are Not Immune From the Short Squeeze Story

There have been an awful lot of shenanigans in the market. Many investors are looking at the low-price penny stocks, but the fallout is spilling over into quality stocks as investors scramble to cover short positions. It’s likely that AbbVie has been one of those stocks.

I presume this is true because the nearly 8% decline in ABBV stock is almost identical to the drop in the share price of companies such as Advanced Micro Devices (NASDAQ:AMD), Apple (NASDAQ:AAPL) and Tesla (NASDAQ:TSLA). You may argue that correlation doesn’t mean causation, but in this case I would beg to differ.

Humira Continues to Deliver

With any biopharma company, investors need to pay careful attention to the pipeline. In the case of AbbVie there was some concern about the upcoming expiration on its lead drug, Humira. The drug already has biosimilar (i.e. generic) competition outside the United States. And if you’re looking to make a bearish argument, you can point to the nearly 10% decline in international sales of Humira in the last quarter.

However the company still holds the patent in the United States for the next couple of years. And domestically, Humira is still driving sales. AbbVie saw domestic sales increase by 8% which meant the company had global sales growth of 4%.

And it’s not like the company is sitting idly by. The company acquired Allergan in May 2020 and will see the benefit of that partnership. For example, Allergan recently announced a warrant agreement with Cypris Medical, a privately held medical device company. The agreement will help expand AbbVie’s portfolio of “facial aesthetics” products that includes Botox Cosmetic.

By Any Measure AbbVie Is a Buy

If you want to measure the company by the numbers, AbbVie continues to outperform the broader market last year. In the last twelve months, ABBV stock is up nearly 24% and that includes its recent dip.

When you look at its performance among other large-cap pharma sector stocks, AbbVie is a clear winner again. The stock’s 24% performance dwarfs the rest of the sector’s 7% growth.

And, its dividend is unassailable. First, Abbvie’s dividend yield of 5.09% (as of this writing) is more than double the industry’s 2.3% average. And a closer look at its sector shows the company has a higher yield than Eli Lilly (NYSE:LLY) with a yield of 1.63% and Pfizer (NYSE:PFE) with a yield of 4.36%.

The Dividend Aristocrat has had 49 consecutive years of growing its dividend, which means it’s knocking on the door of joining the even more elite club of Dividend Kings. Those are companies with at least 50 consecutive years of growing their dividends.

2021 is starting out to be every bit as volatile as its predecessor. At some point, the risk-on trade is going to become a flight to quality and safety. You get both with ABBV stock. And with a pre-earnings dip to boot, the picture doesn’t get to look much better.

Featured Article: Understanding Options Trading


7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future

When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.

The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.

IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.

And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.

But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.

View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)2.7$116.43-0.1%4.47%24.62Buy$117.13
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.